Prestige Consumer Healthcare (PBH) Cash & Equivalents (2010 - 2025)

Prestige Consumer Healthcare's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $62.4 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents rose 22.6% year-over-year to $62.4 million in Q4 2025; TTM through Dec 2025 was $62.4 million, a 22.6% increase from a year earlier, with the FY2025 full-year figure at $97.9 million, up 110.64% from the prior year.
• Cash & Equivalents declined to $62.4 million in Q4 2025 per PBH's latest filing, from $119.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $163.6 million in Q2 2021 and bottomed at $21.0 million in Q4 2021.
• The 5-year median for Cash & Equivalents is $53.1 million (2023), against an average of $64.5 million.
• Biggest YoY gain for Cash & Equivalents was 310.88% in 2022; the steepest drop was 78.08% in 2022.
• Year by year, Cash & Equivalents stood at $21.0 million in 2021, then surged by 310.88% to $86.4 million in 2022, then declined by 26.34% to $63.6 million in 2023, then fell by 20.03% to $50.9 million in 2024, then advanced by 22.6% to $62.4 million in 2025.
• Per Business Quant, the three latest PBH Cash & Equivalents figures stand at $62.4 million (Q4 2025), $119.1 million (Q3 2025), and $139.5 million (Q2 2025).